US ▾
ROROIV

Roivant (ROIV) Q1 FY27 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q1 FY27)· Aug 6, 2026

Source: earnings call transcript

Executive summary

Roivant Q1 FY27 — Brepocitinib DM Launch Imminent, Robust Pipeline Catalysts Ahead

Roivant is entering a period of significant catalysts, highlighted by the imminent potential launch of brepocitinib for dermatomyositis and multiple pipeline data readouts in the second half of 2026. The company is strategically preparing for a "slow and steady" launch for brepocitinib, focusing on long-term market development across multiple indications. Financial strength was bolstered by a $950 million Moderna settlement payment, enabling substantial share repurchases, while R&D investments continue to drive a rich pipeline with numerous potential registrational events and filings anticipated through 2028.

Highlights

4

  • Brepocitinib launch in dermatomyositis (DM) is on track for imminent potential approval and launch by end of September 2026.

  • Initiated Phase III study for brepocitinib in cutaneous sarcoidosis (CS) ahead of schedule, targeting 40,000 US patients.

  • Received initial $950 million payment from Moderna settlement, with $200 million in share repurchases in the quarter.

  • Multiple key data readouts expected in H2 2026, including brepocitinib in NIU and 1402 in PH-ILD and CLE.

Concerns

4

  • Management noted the quarter was "quiet" with "not the most interesting" earnings call, indicating a period of anticipation rather than significant new disclosures.

  • The company's guidance for brepocitinib DM launch is "slow and steady," suggesting initial uptake may not be rapid.

  • Uncertainty regarding the translatability of PVR reductions from PAH to PH-ILD for 1402, which is a risk for the program.

  • Variability in placebo response rates in immunology trials, particularly for the NIU study, is a concern for future readouts.

Guidance & targets

CategoryTargetConfidence
Brepocitinib launch
By end of September
high materiality
High
Brepocitinib NIU study top-line data
Second half of this year
medium materiality
High
1402 PH-ILD Phase II top-line data
Second half of this year
medium materiality
High
1402 DTRA program update
Second half of this year
medium materiality
High
CLE POC study top-line data
Second half of this year
low materiality
High
Brepocitinib cutaneous sarcoidosis Phase III top-line data
2028
medium materiality
High
Commercial launches
3 or more
high materiality
High
Business study readouts
9 or more
high materiality
High
NDA or BLA filings
4-plus
high materiality
High
Proof-of-concept studies
A number of
medium materiality
High

Deals & partnerships

Moderna Patent litigation settlement $950 million

Upfront payment received from settlement.

Pfizer-BioNTech International patent lawsuits

Filed 3 international lawsuits in Canada and UPC in July.

Risks & headwinds

Variability in placebo response rates in immunology trials For upcoming NIU study readout (H2 2026)

Significant variability

Translatability of PVR reductions from PAH to PH-ILD for 1402 For upcoming PH-ILD Phase II data readout (H2 2026)

Not quantified

Mitigation:Study designed with care around emphysema levels to maximize potential benefit.

Initial slow uptake for brepocitinib DM launch Initial launch period (Q3 FY27 and beyond)

Slow and steady

Mitigation:Focusing on building a strong foundation for access, patient support, and scientific communication for long-term opportunity across multiple indications.

JAK class safety concerns for brepocitinib Ongoing

Black Box warnings

Mitigation:Choosing indications like DM where unmet need is high and existing therapies have worse safety profiles; DM patients inherently at risk of some concerns, and treating them well reduces those risks.

What to watch in Q2 FY27

Brepocitinib DM launch progress

Next quarter
Current PDUFA date this quarter, launch expected by end of September.
Target Initial commercial uptake and physician/patient feedback.

Why it matters

This is the company's first major commercial launch, critical for revenue generation and establishing market presence.

Obviously, one of the major events in the near term here is the launch -- potential launch of brepocitinib in dermatomyositis.

Find out whether ROIV delivers this. Inve re-checks your case every morning.

Q&A highlights

What metrics will be provided for the DM launch? For PH-ILD, what are the implications of patients being on nintedanib regarding fibrosis/emphysema ratio and the bar for success (6-minute walk vs. PVR)?

Roivant will not provide extensive detail on DM launch metrics initially, focusing on internal understanding and patient/physician engagement, with more guidance closer to approval. For PH-ILD, the study design considered emphysema. Management expects a clear PVR signal but does not consider 6-minute walk essential for a go/no-go decision, as the study is not powered for it.

“I don't know that we're going to provide a ton of detail in the early days. I think it's important for us mostly to spend our time focused on understanding those dynamics ourselves, getting out, talking to patients, talking to physicians, doing the work we need to do.”

asked by Brian Chin · answered by Matthew Gline

2 min read 6 chapters

Detailed narrative

Brepocitinib Launch Strategy

Roivant is preparing for the imminent potential launch of brepocitinib in dermatomyositis (DM), emphasizing a "slow and steady" approach. This strategy aims to build a strong foundation for access, patient support, and scientific communication, not just for DM but also for future indications like NIU, cutaneous sarcoidosis (CS), and lichen planopilaris (LPP). The company believes this measured approach will maximize the long-term opportunity across all potential indications, rather than focusing solely on rapid initial uptake in DM.

Pipeline Progress and Upcoming Catalysts

The company highlighted significant progress across its pipeline, including the initiation of a Phase III study for brepocitinib in cutaneous sarcoidosis, ahead of schedule. Multiple key data readouts are anticipated in the second half of 2026, including top-line data for brepocitinib in non-infectious uveitis (NIU), 1402 in PH-ILD (pulmonary hypertension associated with interstitial lung disease), and a proof-of-concept study in cutaneous lupus erythematosus (CLE). Updates on the 1402 difficult-to-treat RA program are also expected.

Cutaneous Sarcoidosis (CS) Program

The Phase III study for brepocitinib in CS has begun enrolling patients, targeting a high-unmet-need population of approximately 40,000 patients in the US. The study design incorporates learnings from the successful Phase II, which showed a greater than 20-point benefit on the CSAMI scale compared to placebo. The pivotal program is a 16-week, 140-patient study with a primary endpoint of CSAMI >= 50% response rate, with top-line data expected in 2028.

PH-ILD Program (1402)

Management discussed the 1402 program for PH-ILD, noting the study's design carefully considered emphysema levels to maximize potential benefit. While the study is not powered for 6-minute walk distance, the focus is on achieving a clear signal on PVR (pulmonary vascular resistance) as an approvable therapy. The translatability of PVR reductions from PAH to PH-ILD is a key question the study aims to answer, with results expected in H2 2026.

Financial Update and Capital Allocation

Roivant reported approximately $200 million in R&D expense and $166 million in GAAP G&A for the quarter. The company's cash balance was just under $4 billion, prior to a $72 million receipt. Following the Moderna settlement, Roivant accelerated its share repurchase program, buying back approximately $200 million in shares during the quarter at an average price in the high $20s, demonstrating a commitment to returning capital to shareholders.

Litigation Updates

The company received the upfront $950 million payment from the Moderna settlement. Progress continues on the 4098 patent ruling at the Federal Circuit, which could yield an additional $1.3 billion. Roivant also filed three international lawsuits against Pfizer-BioNTech in July, including in Canada and the UPC, actively pursuing potential further recoveries.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.